GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxcyte Inc (FRA:5VA) » Definitions » Institutional Ownership

Vaxcyte (FRA:5VA) Institutional Ownership : 83.65% (As of Jun. 13, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Vaxcyte Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Vaxcyte's institutional ownership is 83.65%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Vaxcyte's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Vaxcyte's Float Percentage Of Total Shares Outstanding is 86.36%.


Vaxcyte Institutional Ownership Historical Data

The historical data trend for Vaxcyte's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxcyte Institutional Ownership Chart

Vaxcyte Historical Data

The historical data trend for Vaxcyte can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 79.59 80.29 78.59 79.50 80.59 82.50 76.33 83.88 83.68 83.65

Vaxcyte Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Vaxcyte (FRA:5VA) Business Description

Traded in Other Exchanges
Address
825 Industrial Road, Suite 300, San Carlos, CA, USA, 94070
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-XP, VAX-A1, and VAX-PG.

Vaxcyte (FRA:5VA) Headlines

No Headlines